-
Thorac Cancer: Efficacy of crizotinib-alatinib continuous regimen in the treatment of Chinese patients with advanced ALK-positive NSCLC
Time of Update: 2021-12-25
Therefore, a number of domestic hospital teams have jointly carried out related studies to evaluate the efficacy of crizotinib-alatinib continuous regimen in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) in China .
-
Why is the risk of male breast cancer in this cohort soaring!
Time of Update: 2021-12-25
Although the estimates are not statistically significantThis time we report on the obvious occupational risk of male breast cancer, hoping to inspire further research in the future .
Excess risk of male breast cancer in the Norwegian Offshore Petroleum Workers (NOPW) cohort: a possible link to extreme night shift work?
-
Clin Cancer Res: TIGIT antibody Etigilimab ± nivolumab in the treatment of advanced solid tumors
Time of Update: 2021-12-25
immunityThis is the first open-label, multi-center, dose-escalation, and expanded phase 1a/b clinical trial in humans, recruiting patients with locally advanced or metastatic solid tumors .
The 3+3 design was adopted, and the test patients received a 14-day treatment course: anti-TIGIT antibody Etigilimab monotherapy (Phase 1a: 0.
-
What is the MET gene abnormality in lung cancer?
Time of Update: 2021-12-25
As we all know, EGFR and ALK are the two most classic driver genes in lung cancer, and abnormalities in the MET pathway are different from these two types of mutations, including 4 types of MET overexpression, MET amplification, MET14 exon skip mutation, and MET fusion.
-
Lancet Oncol: The efficacy of carfilzomib, darelimumab and dexamethasone in the treatment of relapsed or refractory multiple myeloma
Time of Update: 2021-12-25
Compared with the Kd regimen, the KdD regimen has a clear and sustained progression-free survival benefit in patients with relapsed or refractory multiple myeloma.
-
Cell Reports: Potential star anti-cancer targets may promote cancer?
Time of Update: 2021-12-24
However, a recent study by a research team at the University of California, San Diego showed that Shp2 as a therapeutic target can also promote disease progression , which has raised concerns about the development of anticancer drugs that target Shp2 .
-
J Clin Oncol: Efficacy and safety of T-DM1 + Pertuzumab vs. Taxanes + Trastuzumab + Pertuzumab in the treatment of high-risk HER2+ early breast cancer patients: Phase III clinical study KAITLIN
Time of Update: 2021-12-24
Recently, the Journal of Clinical Oncology published the results of a phase III clinical study KAITLIN (NCT01966471), which compares T-DM1+pertuzumab with taxanes+trax in high-risk HER2+ early breast cancer (EBC) patients Efficacy and safety of touzumab+pertuzumab treatment .
-
Clin Cancer Res: The effect of Adavosertib combined with chemotherapy in the treatment of platinum-resistant ovarian cancer, fallopian tube cancer and peritoneal cancer
Time of Update: 2021-12-24
This study aimed to evaluate the efficacy, safety and pharmacokinetics of adavosertib combined with four commonly used chemotherapy drugs in the treatment of patients with primary platinum-resistant ovarian cancer, fallopian tube cancer, and peritoneal cancer .
-
J Thromb Haemost: The incidence of hemophagocytic lymphohistiocytosis in adults and the incidence of thromboembolism and its impact on overall survival
Time of Update: 2021-12-24
Incidence of bleeding and thromboembolism and impact on overall survival in adult patients with hemophagocytic lymphohistiocytosis: A 20-year provincial retrospective cohort study .
15615 Original Source: Incidence of Bleeding and thromboembolism and Impact ON Overall Survival in Adult patients with hemophagocytic lymphohistiocytosis: A 20-year Provincial Retrospective cohort Study in this message
-
J Natl Cancer Inst: A tumor infiltrating lymphocyte imaging marker for risk stratification of HPV-related oropharyngeal cancer!
Time of Update: 2021-12-24
001) OP-TIL divided patients with stage I HPV-related OPSCC with a history of smoking ≤30 packs/year into a low-risk group (2 years disease-free survival Rate [DFS] 94.
-
Lancet: Global life expectancy forecast map in 2040 (including Chinese data)
Time of Update: 2021-12-24
2016 and 2040 forecasts leading to the top 10 causes of YLLs in high blood pressure .
Conditions in different countries Forecasting life expectancy, years of life lost, and all-cause and cause-specific Mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories.
-
Innovative anti-tumor drug YS-ON-001 starts phase I clinical trial in Tianjin
Time of Update: 2021-12-24
On December 9, 2021, the Phase I clinical trial of YS-ON-001, an innovative drug independently developed by EsenBio, was held in Tianjin Cancer Hospital .
The Phase I clinical trial of YS-ON-001 project proposes that the drug is indicated for advanced breast cancer, advanced lung cancer, advanced liver cancer and advanced melanoma.
-
JAMA Oncol: Analysis of related factors of treatment regret in local prostate cancer patients
Time of Update: 2021-12-24
Recently, researchers from the United States published an article in the "JAMA Oncol" magazine, evaluating the treatment of local prostate cancer patients, functional outcomes, and the relationship between patient expectations and treatment regrets .
-
J INTERN MED: Incidence and survival rate of hemophagocytic lymphohistiocytosis
Time of Update: 2021-12-24
Researchers used population-based linked data from England's primary care, secondary care, cancer registry, and mortality database to determine the diagnosis of hemophagocytic lymphohistiocytosis between January 1, 2000 and December 31, 2016 Individual .
Incidence and survival of haemophagocytic lymphohistiocytosis: A population-based cohort study from England .
-
The guide recommends "2021 CSCO Kidney Cancer Diagnosis and Treatment Guide"
Time of Update: 2021-12-24
Please scan the QR code to download the APP directly Download link: Metz Medicine APP Tip: 78% of users have downloaded Metz Medicine APP , which is more convenient to read and communicate.
-
never expected!
Time of Update: 2021-12-24
Papillary thyroid carcinomaThe included 45 studies investigated the possible relationship between HT and PTC .
Only two studies evaluated the relationship between undifferentiated thyroid cancer (ATC) and HT, and the incidence of TC in the HT group was 0 and 1.
-
CMAJ: Study on the incidence of cancer in children in Canada during the COVID-19 pandemic (No. 26)
Time of Update: 2021-12-24
During the first 9 months of the COVID-19 pandemic, we did not observe a statistically significant change in the incidence of childhood cancer or the proportion of children who participated in clinical trials, showed metastatic disease or died prematurely, the report shows , In Canada, the chances of childhood cancer patients' access to medical care have not been significantly reduced .
-
Oral Dis: topical vitamin D gel can reduce the development of oral mucositis and relieve pain
Time of Update: 2021-12-24
Vitamin D preventionThe study finally included 45 patients with head and neck cancer and conducted a three-arm randomized controlled clinical trial: the first group was the conventional treatment group; the second group was the topical oral vitamin D gel; the third group was the topical oral vitamin D gel combination Routine treatment .
-
J Clin Oncol: Efficacy and safety of CHOP regimen plus romidepsin in the treatment of relapsed/refractory peripheral T-cell lymphoma
Time of Update: 2021-12-24
In summary, on the basis of the CHOP regimen, the addition of romidepsin did not improve the progression-free survival, remission rate and overall survival of patients with previously untreated peripheral T-cell lymphoma, and it also increased ≥3 grades The incidence of adverse events requiring urgent treatment .
-
Clinical Guidelines for Radiotherapy of Non-Small Cell Lung Cancer in China (2020 Edition)
Time of Update: 2021-12-24
Source: Chinese Journal of Radiation OncologySource: Chinese Journal of Radiation Oncology Source: Chinese Journal of Radiation OncologyCite this article: Chinese Medical Association Radiation Oncology Therapeutics Branch, Chinese Medical Doctor Association Radiation Oncology Therapeutics Branch, Chinese Anti-Cancer Association Radiotherapy Professional Committee, Chinese Clinical Oncology Society Tumor Radiotherapy Expert Committee.
